Omeros Co. (NASDAQ:OMER) Receives Average Rating of “Moderate Buy” from Brokerages

Omeros Co. (NASDAQ:OMER) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $22.50.

Several equities analysts have commented on OMER shares. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 target price on the stock. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Thursday, January 16th.

Hedge Funds Weigh In On Omeros

Large investors have recently made changes to their positions in the business. Truvestments Capital LLC boosted its holdings in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 1,972 shares during the period. Quantbot Technologies LP acquired a new position in shares of Omeros in the fourth quarter worth about $46,000. Picton Mahoney Asset Management boosted its holdings in shares of Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 4,404 shares during the period. Finally, US Bancorp DE acquired a new position in shares of Omeros in the fourth quarter worth about $81,000. Institutional investors own 48.79% of the company’s stock.

Omeros Trading Up 0.7 %

Omeros stock opened at $9.18 on Tuesday. The stock has a market cap of $531.98 million, a price-to-earnings ratio of -3.97 and a beta of 1.98. The company’s 50-day moving average price is $9.31 and its two-hundred day moving average price is $6.60. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.